索拉菲尼对行肝动脉化疗栓塞术治疗的BCLC B/C期肝细胞癌患者的疗效

doi:10.3969/j.issn.2095-9400.2019.08.009

Abstract
Figure/Table
References (0)
Related Citation (4)

Download: PDF (2027 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To explore the synergistic effect of the sorafenib on the efficacy of BCLC B/C hepatocellular carcinoma (HCC) patients treated with transcatheter arterial chemoembolization (TACE). Methods: Eighty-four patients with BCLC stage B/C hepatocellular carcinoma who were treated with TACE in our hospital from January 2013 to December 2017 were retrospectively selected. All patients were confirmed as hepatocellular carcinoma by biopsy, and further divided into TACE group (45 patients) and the sorafenib combined with TACE group (combination group, 39 patients) according to the presence or absence of sorafenib. All enrolled patients were followed up for three years, and clinical data were recorded. The disease control and survival benefits between the two groups were compared, and the synergistic effect of sorafenib on TACE was determined. Results: The tumor response of the combination group (64.1%) was significantly better than that of the TACE group (37.21%) (P=0.008). The 6-month, 1-year, 2-year and 3-year survival rates of patients in the TACE group were 60%, 40%, 13.3% and 8.9%, respectively, and those in the combination group were 82.1%, 51.3%, 30.8% and 16.9%. The overall survival time of the TACE group and the combination group was 12.9 months and 19.3 months, respectively; the progression-free survival time was 6.044 months and 16.218 months, respectively. The overall survival time (P=0.032) and progression-free survival time (P=0.006) of the combination group were significantly better than that of TACE group. Conclusion: For BCLC B/C stage HCC patients treated with TACE, sorafenib could significantly benefit the overall survival of patients and improve the TACE efficacy of HCC.

Key words： sorafenib transcatheter arterial chemoembolization hepatocellular carcinoma Barcelona Clinic Liver Cancer stage survival time

	Service
	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHENG Shimiao
	LUO Songmei
	LI Li
	LYU Xiuling
	WU Xulu
	WENG Qiaoyou
	CHEN Minjiang
	YANG Hongyuan
	JI Jiansong

URL:

https://xb.wmu.edu.cn/EN/10.3969/j.issn.2095-9400.2019.08.009 OR https://xb.wmu.edu.cn/EN/Y2019/V49/I8/594

[1] SIA D, VILLANUEVA A, FRIEDMAN S L, et al. Liver cancer cell of origin, molecular class, and effects on patient prognosis[J]. Gastroenterology, 2017, 152(4): 745-761.
[2] JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J]. CA Cancer J Clin, 2011, 61(2): 69-90.
[3] POKURI V K, TOMASZEWSKI G M, AIT-OUDHIA S,
et al. Efficacy, safety, and potential biomarkers of sunitinib and transarterial chemoembolization (TACE) combination in advanced hepatocellular carcinoma (HCC): Phase II trial[J]. Am J Clin Oncol, 2018, 41(4): 332-338.
[4] GALLE P R, FORNER A, LLOVET J M, et al. EASL clinical practice guidelines: management of hepatocellular carci-noma[J]. J Hepatol, 2018, 69(1): 182-236.
[5] SIEGHART W, HUCKE F, PECK-RADOSAVLJEVIC M. Transarterial chemoembolization: modalities, indication, and patient selection[J]. J Hepatol, 2015, 62(5): 1187-1195.
[6] YANG J D, AQEL B A, PUNGPAPONG S, et al. Direct acting antiviral therapy and tumor recurrence after liver transplantation for hepatitis C-associated hepatocellular carcino-ma[J]. J Hepatol, 2016, 65(4): 859-860.
[7] 吴发宗, 吕秀玲, 宋晶晶, 等. 阿帕替尼联合肝动脉化疗栓塞术的抗肝癌疗效及对肿瘤血管再生的影响[J]. 温州医科大学学报, 2019, 49(6): 423-426.
[8] 赵鹏, 陈东, 陈伟, 等. 索拉菲尼治疗晚期原发性肝细胞癌的疗效及其预测因素[J]. 中华外科杂志, 2012, 50(6): 514-517.
[9] 张惠洁, 郭卫东. 索拉菲尼在肿瘤治疗中的研究进展[J]. 中华临床医师杂志(电子版), 2013, 7(1): 137-139.
[10] 丁文金, 李飞平, 龚光文, 等. TACE联合索拉菲尼与TACE治疗巴塞罗那B期肝癌的临床对比研究[J]. 肿瘤药学, 2015(3): 230-234.
[11] 杨明, 罗克品, 谢岳云, 等. 肝动脉化疗栓塞联合索拉菲尼治疗中晚期肝细胞癌[J]. 肝胆胰外科杂志, 2013, 25(4): 265-268.
[12] 付元, 纪建松, 涂建飞, 等. TACE联合RFA及索拉菲尼在肝癌外科术后复发治疗中的临床应用[J]. 介入放射学杂志, 2015, 24(12): 1067-1071.